Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Marshall Wace LLP

Marshall Wace LLP boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 27.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,051,573 shares of the biopharmaceutical company's stock after acquiring an additional 229,561 shares during the quarter. Marshall Wace LLP owned 1.14% of Ultragenyx Pharmaceutical worth $44,240,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in RARE. Smartleaf Asset Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at $35,000. Human Investing LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $42,000. Van ECK Associates Corp increased its holdings in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 273 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $83,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on RARE shares. Wells Fargo & Company raised their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a report on Friday, December 20th. JPMorgan Chase & Co. boosted their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. HC Wainwright reaffirmed a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Cantor Fitzgerald reissued an "overweight" rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Finally, Piper Sandler cut their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $92.79.

Insider Activity

In other news, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the sale, the executive vice president now directly owns 54,991 shares in the company, valued at $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emil D. Kakkis sold 73,434 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $3,091,571.40. Following the transaction, the chief executive officer now owns 641,731 shares of the company's stock, valued at $27,016,875.10. This represents a 10.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 124,643 shares of company stock worth $5,256,268 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Trading Up 2.0 %

RARE stock opened at $35.69 on Friday. The company's 50-day moving average price is $38.57 and its 200 day moving average price is $44.40. Ultragenyx Pharmaceutical Inc. has a 52 week low of $29.59 and a 52 week high of $60.37. The company has a market cap of $3.35 billion, a P/E ratio of -5.63 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $164.88 million for the quarter, compared to analysts' expectations of $163.23 million. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.